Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ACRX

ACRX - AcelRx Pharmaceuticals Inc Stock Price, Fair Value and News

$1.000.00 (0.00%)
Market Closed

15/100

ACRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

15/100

ACRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.8

Target 3M

$0.9

Target 6M

$0.85

ACRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ACRX Price Action

Last 30 days

-11.5%

Last 90 days

-13.0%

Trailing 12 Months

40.8%

ACRX RSI Chart

ACRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ACRX Valuation

Market Cap

46.6M

Price/Earnings (Trailing)

-3.76

Price/Sales (Trailing)

158.54

EV/EBITDA

-4.32

Price/Free Cashflow

-4.17

ACRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.8

Target 3M

$0.9

Target 6M

$0.85

ACRX Fundamentals

ACRX Revenue

Revenue (TTM)

294.0K

Rev. Growth (Yr)

-47.74%

Rev. Growth (Qtr)

-2.41%

ACRX Earnings

Earnings (TTM)

-12.4M

Earnings Growth (Yr)

-32.3%

Earnings Growth (Qtr)

-27.14%

ACRX Profitability

EBT Margin

-3561.41%

Return on Equity

-64.6%

Return on Assets

-40.3%

Free Cashflow Yield

-23.99%

ACRX Investor Care

Shares Dilution (1Y)

173.70%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025486.0K368.0K294.0K0
20241.4M779.0K747.0K679.0K
202363.4M42.7M22.1M1.4M
202223.1M43.4M63.7M84.1M
20215.5M3.1M3.6M2.8M
20202.2M4.2M5.0M5.4M
20192.4M2.6M2.8M2.5M
20185.2M3.4M2.3M2.2M
201717.4M15.6M13.7M8.0M
201622.1M24.7M12.7M17.4M
20158.7M12.2M15.8M19.3M
201423.4M17.4M11.3M5.2M
20133.0M3.2M3.6M29.5M
20121.4M1.7M2.1M2.4M
20110001.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About AcelRx Pharmaceuticals Inc

ACRX
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.
 CEO
 WEBSITEacelrx.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES19

AcelRx Pharmaceuticals Inc Frequently Asked Questions

ACRX is the stock ticker symbol of AcelRx Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jan 26 2026, market cap of AcelRx Pharmaceuticals Inc is 46.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ACRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether ACRX is over valued or under valued. Whether AcelRx Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact AcelRx Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRX.

As of Mon Jan 26 2026, ACRX's PE ratio (Price to Earnings) is -3.76 and Price to Sales (PS) ratio is 158.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, AcelRx Pharmaceuticals Inc has provided -0.35 (multiply by 100 for percentage) rate of return.